Role of low-molecular-weight heparins in the treatment of sudden hearing loss.
For the present, no definitive treatment is universally accepted for sudden sensorineural hearing loss (SNHL). The goal of this study was to evaluate the role of low-molecular-weight heparins in its therapeutic regimen. A retrospective analysis has been taken in 100 patients with SNHL in which they were divided into 2 groups: 50 patients received commonly therapy added with and without low-molecular-weight heparins each. The audiogrametric data at pretreatment were compared with data at day 10 and with data collected at follow-up (average 20 days). The results showed that there was a significant improvement for early or late audiometric outcome in group 1 when compared with group 2 (P <.05). Forty-three patients (86%) were classified into recovery or good improvement in group 1, which was higher than group 2 (P <.01). The improvement rate was calculated for each of the 100 patients, and the average value was 84. Seventy percent in group 1 and 70% in group 2. It is concluded that the use of low-molecular-weight heparins not only considerably improve the curative rate in the hearing improvement of sudden sensorineural hearing loss but without such potential risk as unfractionated heparins.